Legal News, In Brief: FDA Opposes Otsuka Suit; Apotex Can Challenge Benicar Patent
Executive Summary
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.
You may also be interested in...
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.
Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.
COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: